Esketamine for major depressive disorder

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 7 registered trials.

Why this status

  1. 1 Feb 2017: Trial registered, NCT03039192
  2. 31 Mar 2017: Trial registered, NCT03097133
  3. 9 Jun 2017: Trial started, NCT03039192
  4. 15 Jun 2017: Trial started, NCT03097133
  5. 8 Apr 2020: Trial registered, NCT04338321
  6. 21 Aug 2020: Trial started, NCT04338321

The trials

NCT01640080: A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression

State
Completed
Phase
Phase 2
People
30 taking part
Started
27 Jun 2012
Primary completion
3 Jun 2013
Arms
Esketamine (Group 1), Esketamine (Group 2)
Results
None posted
  1. 27 Jun 2012: Trial started
  2. 13 Jul 2012: Trial registered
  3. 3 Jun 2013: Trial completed

NCT03039192: 54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

State
Completed
Phase
Phase 3
People
226 taking part
Started
9 Jun 2017
Primary completion
18 Dec 2018
Arms
Esketamine + Standard of care
Results
Posted on the registry
  1. 1 Feb 2017: Trial registered
  2. 9 Jun 2017: Trial started
  3. 18 Dec 2018: Trial completed
  4. 29 Oct 2020: Trial results posted

NCT03097133: 54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide

State
Completed
Phase
Phase 3
People
230 taking part
Started
15 Jun 2017
Primary completion
11 Apr 2019
Arms
Esketamine + Standard of care
Results
Posted on the registry
  1. 31 Mar 2017: Trial registered
  2. 15 Jun 2017: Trial started
  3. 11 Apr 2019: Trial completed
  4. 25 Sep 2020: Trial results posted

NCT03965858: Efficacy, Safety and Pharmacokinetic Study of Inhaled Esketamine in Treatment-resistant Depression

State
Completed
Phase
Phase 2
People
88 taking part
Started
25 Feb 2019
Primary completion
15 Mar 2020
Arms
Esketamine low dose, Esketamine medium dose, Esketamine high dose
Results
None posted
  1. 25 Feb 2019: Trial started
  2. 29 May 2019: Trial registered
  3. 24 Apr 2020: Trial completed

NCT04338321: A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder

State
Completed
Phase
Phase 3
People
676 taking part
Started
21 Aug 2020
Primary completion
20 Jan 2022
Arms
Esketamine Arm
Results
Posted on the registry
  1. 8 Apr 2020: Trial registered
  2. 21 Aug 2020: Trial started
  3. 15 Jul 2022: Trial completed
  4. 15 Feb 2023: Trial results posted

NCT04924257: ECT vs. Esketamine

State
Withdrawn before it started
Phase
Phase 3
People
0 taking part
Started
28 Jul 2021
Primary completion
Aug 2023
Arms
Intranasal Esketamine
Results
None posted
  1. 11 Jun 2021: Trial registered
  2. 28 Jul 2021: Trial started
  3. 5 Aug 2022: Trial withdrawn

NCT05554627: VA Aripiprazole vs Esketamine for Treatment Resistant Depression

State
Withdrawn before it started
Phase
Phase 4
People
0 taking part
Started
27 Oct 2023
Primary completion
27 Oct 2023
Arms
Esketamine
Results
None posted
  1. 26 Sep 2022: Trial registered
  2. 27 Oct 2023: Trial started
  3. 5 Jan 2024: Trial withdrawn

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Esketamine (Intranasal Spray), Esketamine 28 mg, Esketamine 56 mg, Esketamine 84 mg, Esketamine DPI - high dose, Esketamine DPI - low dose, Esketamine DPI - medium dose, Esketamine Nasal Product, Esketamine Nasal Spray, Intranasal esketamine (28 mg), Intranasal esketamine (56 mg), Intranasal esketamine (84 mg), Keta-s, Ketaved.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.